🚀 VC round data is live in beta, check it out!
Guizhou Sanli Valuation Multiples
Discover revenue and EBITDA valuation multiples for Guizhou Sanli and similar public comparables like Gyre Therapeutics, Zentiva, Abclon, Aarti Pharmalabs and more.
Guizhou Sanli Overview
About Guizhou Sanli
Guizhou Sanli Pharmaceutical Co Ltd is engaged in Chinese pharmaceutical research, development, production and marketing. The company produces and sells soft capsules, hard capsules, sprays (including Chinese medicine extraction) and provides Chinese medicine science and technology consulting services. Its products include Pediatric medication; Respiratory system medication; Cardiovascular and cerebrovascular drugs; Digestive medicine; Trauma injury medication; Rehabilitation medicine; and Ophthalmic medicine.
Founded
1995
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$731M
Guizhou Sanli Financials
Guizhou Sanli reported last 12-month revenue of $216M.
In the same LTM period, Guizhou Sanli generated $145M in gross profit and $20M in net income.
Revenue (LTM)
Guizhou Sanli P&L
In the most recent fiscal year, Guizhou Sanli reported revenue of $314M and EBITDA of $61M.
Guizhou Sanli expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $216M | XXX | $314M | XXX | XXX | XXX |
| Gross Profit | $145M | XXX | $219M | XXX | XXX | XXX |
| Gross Margin | 67% | XXX | 70% | XXX | XXX | XXX |
| EBITDA | — | XXX | $61M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 19% | XXX | XXX | XXX |
| EBIT Margin | 11% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $20M | XXX | $40M | XXX | XXX | XXX |
| Net Margin | 9% | XXX | 13% | XXX | XXX | XXX |
| Net Debt | — | — | $13M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Guizhou Sanli Stock Performance
Guizhou Sanli has current market cap of $660M, and enterprise value of $731M.
Market Cap Evolution
Guizhou Sanli's stock price is $1.61.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $731M | $660M | -1.6% | XXX | XXX | XXX | $0.10 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGuizhou Sanli Valuation Multiples
Guizhou Sanli trades at 3.4x EV/Revenue multiple, and 12.0x EV/EBITDA.
EV / Revenue (LTM)
Guizhou Sanli Financial Valuation Multiples
As of April 11, 2026, Guizhou Sanli has market cap of $660M and EV of $731M.
Equity research analysts estimate Guizhou Sanli's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Guizhou Sanli has a P/E ratio of 32.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $660M | XXX | $660M | XXX | XXX | XXX |
| EV (current) | $731M | XXX | $731M | XXX | XXX | XXX |
| EV/Revenue | 3.4x | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 12.0x | XXX | XXX | XXX |
| EV/EBIT | 30.2x | XXX | 14.3x | XXX | XXX | XXX |
| EV/Gross Profit | 5.1x | XXX | 3.3x | XXX | XXX | XXX |
| P/E | 32.4x | XXX | 16.4x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 80.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Guizhou Sanli Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Guizhou Sanli Margins & Growth Rates
Guizhou Sanli's revenue in the last 12 month grew by 5%.
Guizhou Sanli Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | (32%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 11% | XXX | XXX | XXX |
| S&M Expenses to Revenue | 46% | XXX | 41% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 7% | XXX | 6% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2% | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 53% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Guizhou Sanli Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Gyre Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Zentiva | XXX | XXX | XXX | XXX | XXX | XXX |
| Abclon | XXX | XXX | XXX | XXX | XXX | XXX |
| Aarti Pharmalabs | XXX | XXX | XXX | XXX | XXX | XXX |
| Tempo Scan Pacific | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Guizhou Sanli M&A Activity
Guizhou Sanli acquired XXX companies to date.
Last acquisition by Guizhou Sanli was on XXXXXXXX, XXXXX. Guizhou Sanli acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Guizhou Sanli
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGuizhou Sanli Investment Activity
Guizhou Sanli invested in XXX companies to date.
Guizhou Sanli made its latest investment on XXXXXXXX, XXXXX. Guizhou Sanli invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Guizhou Sanli
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Guizhou Sanli
| When was Guizhou Sanli founded? | Guizhou Sanli was founded in 1995. |
| Where is Guizhou Sanli headquartered? | Guizhou Sanli is headquartered in China. |
| Is Guizhou Sanli publicly listed? | Yes, Guizhou Sanli is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Guizhou Sanli? | Guizhou Sanli trades under 603439 ticker. |
| When did Guizhou Sanli go public? | Guizhou Sanli went public in 2020. |
| Who are competitors of Guizhou Sanli? | Guizhou Sanli main competitors are Gyre Therapeutics, Zentiva, Abclon, Aarti Pharmalabs. |
| What is the current market cap of Guizhou Sanli? | Guizhou Sanli's current market cap is $660M. |
| What is the current revenue of Guizhou Sanli? | Guizhou Sanli's last 12 months revenue is $216M. |
| What is the current revenue growth of Guizhou Sanli? | Guizhou Sanli revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Guizhou Sanli? | Current revenue multiple of Guizhou Sanli is 3.4x. |
| Is Guizhou Sanli profitable? | Yes, Guizhou Sanli is net-income-positive (as of the last 12 months). |
| What is the current net income of Guizhou Sanli? | Guizhou Sanli's last 12 months net income is $20M. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.